Log in with your email address username.


[Comment] Isavuconazole: a role for the newest broad-spectrum triazole

Invasive mould infection is a serious complication of treatment for acute leukaemia and transplantation and is increasingly identified with other underlying disorders.1,2 In The Lancet, Johan Maertens and colleagues3 report a randomised, double-blind, non-inferiority study comparing a new broad-spectrum triazole, isavuconazole, with the current standard treatment, voriconazole, in 516 adult patients with suspected invasive mould infection. Isavuconazole was non-inferior to voriconazole by the primary endpoint of all-cause mortality at day 42 (19% [48 patients] in the isavuconazole group vs 20% [52 patients] in the voriconazole group) in an intention-to-treat population.